Leerink Partners Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by Leerink Partners from $980.00 to $862.00 in a research note issued to investors on Tuesday. They currently have a market perform rating on the biopharmaceutical company’s stock.

REGN has been the subject of several other reports. TD Cowen lowered their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Canaccord Genuity Group began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Finally, Royal Bank of Canada cut their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $983.65.

Regeneron Pharmaceuticals Trading Up 4.5 %

Shares of REGN stock opened at $697.05 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market cap of $76.60 billion, a P/E ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08. The business has a 50-day moving average price of $719.16 and a two-hundred day moving average price of $918.90. Regeneron Pharmaceuticals has a 12-month low of $642.00 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.86 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals will post 37.75 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.50%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of REGN. Adirondack Trust Co. grew its position in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock valued at $453,000 after purchasing an additional 10 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 10 shares during the last quarter. Trust Co. of Vermont increased its position in shares of Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 12 shares in the last quarter. Nvwm LLC raised its holdings in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 14 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 3.6% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 15 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.